Beximco Pharmaceuticals PLC. (DSE:BXPHARMA)
Bangladesh · Delayed Price · Currency is BDT 150.00
-0.60 (-0.40%)
At close: Jul 6, 2026
DSE:BXPHARMA Revenue
Beximco Pharmaceuticals PLC. had revenue of 13.63B BDT in the quarter ending March 31, 2026, with 8.08% growth. This brings the company's revenue in the last twelve months to 53.93B, up 12.43% year-over-year. In the fiscal year ending June 30, 2025, Beximco Pharmaceuticals PLC. had annual revenue of 49.12B with 10.65% growth.
Revenue (ttm)
53.93B
Revenue Growth
+12.43%
P/S Ratio
1.24
Revenue / Employee
44.09M
Employees
1,122
Market Cap
66.92B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 49.12B | 4.73B | 10.65% |
| Jun 30, 2024 | 44.39B | 5.12B | 13.05% |
| Jun 30, 2023 | 39.27B | 4.60B | 13.26% |
| Jun 30, 2022 | 34.67B | 5.18B | 17.55% |
| Jun 30, 2021 | 29.49B | 3.88B | 15.16% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Square Pharmaceuticals PLC. | 83.53B |
| Renata | 44.93B |
| The ACME Laboratories | 40.05B |
| Beacon Pharmaceuticals | 15.57B |
| The IBN SINA Pharmaceutical Industry | 13.48B |
| Navana Pharmaceuticals | 10.57B |
| Unilever Consumer Care | 3.49B |
| Techno Drugs | 3.10B |
Beximco Pharmaceuticals PLC. News
- 1 year ago - Small Cap Stocks: Indus Gas, VAST Resources, Beximco - The Armchair Trader